NMPA granted designation for TTFields targeting pancreatic cancer, with Zai Lab participating in a study in Greater China.
2 reports, 1 independent
Updated Aug 19
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NMPA granted designation for TTFields targeting pancreatic cancer, with Zai Lab participating in a study in Greater China.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.NMPA grants designation for TTFields for pancreatic cancer; Zai Lab participates in Greater China study.1 source
- Zai Lab enrolled substantial patients in its clinical trial in China.
Keep exploring
The entities involved
-
Zai Lab Limited
Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.
Nothing else this week.
Coverage
Newest first; wire copies grouped- Business WireZai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer SHANGHAI & CAMBRIDGE, Mass.
- Unknown outlet